Nonclinical safety of ziconotide: An intrathecal analgesic of a new pharmaceutical class

International Journal of Toxicology

Volumn 26, Issue 5, 2007, Pages 411-421

  Skov, Michael J ^a   Beck, James C ^b   De Kater, Annelies W ^c   Shopp, George M ^d  

^a ELAN PHARMACEUTICALS   (United States)

^b Roche   (United States)

^c Pain Therapeutics Inc   (United States)

^d Shopp Nonclinical Consulting LLC   (United States)

Author keywords

Intrathecal; Safety; Toxicology; Ziconotide

Indexed keywords

ANALGESIC AGENT; DRUG ANTIBODY; OMEGA CONOTOXIN MVIIA;

ACUTE TOXICITY; ANAPHYLAXIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ATAXIA; CARCINOGENIC ACTIVITY; CARDIOTOXICITY; CELL PROLIFERATION; CHRONIC TOXICITY; CONTINUOUS INFUSION; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GRANULOMA; GUINEA PIG; HISTOPATHOLOGY; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MONKEY; MOUSE; MUTAGENIC ACTIVITY; NONHUMAN; PREDICTION; RABBIT; RAT; REPRODUCTIVE TOXICITY; TERATOGENICITY; TOXICITY TESTING; TREMOR;

ACUTE TOXICITY TESTS; AMINO ACID SEQUENCE; ANALGESICS, NON-NARCOTIC; ANIMALS; CARCINOGENICITY TESTS; DOGS; DRUG EVALUATION, PRECLINICAL; EMBRYONIC DEVELOPMENT; FETAL DEVELOPMENT; GUINEA PIGS; INFUSIONS, INTRA-ARTERIAL; INJECTIONS, SPINAL; MACACA FASCICULARIS; MICE; MICE, INBRED STRAINS; MOLECULAR SEQUENCE DATA; MUTAGENICITY TESTS; OMEGA-CONOTOXINS; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; TOXICITY TESTS, CHRONIC;

CANIS FAMILIARIS; CAVIA; MUS; ORYCTOLAGUS CUNICULUS; RATTUS;

EID: 35648932526     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1080/10915810701582970     Document Type: Article

References (28)

1. Bowersox, S., J. Mandema, K. Tarczy-Hornoch, G. Miljanich, and R. R. Luther. 1997. Pharmacokinetics of SNX-111, a selective N-type calcium channel blocker, in rats and cynomolgus monkeys. Drug Metab. Dispos. 25:379-383.
2. Bowersox, S. S., and R. Luther. 1998. Pharmacotherapeutic potential of omega-conotoxin MVIIA (SNX-111), an N-type neuronal calcium channel blocker found in the venom of Conus magus. Toxicon. 36:1651-1658.
3. Bowersox, S. S., T. Singh, L. Nadasdi, Z. Zukowska-Grojec, K. Valentino, and B. B. Hoffman. 1992. Cardiovascular effects of omega-conopeptides in conscious rats: mechanisms of action. J. Cardiovasc. Pharmacol. 20:756-764.
4. Breslin, W. J., H. D. Kirk, and M. A. Zimmer. 1989. Teratogenic evaluation of a polybromodiphenyl oxide mixture in New Zealand white rabbits following oral exposure. Fundam. Appl. Toxicol. 12:151-157.
5. Dean, R. R., S. S. Bowersox, and R. R. Luther. 1995. Effects of SNX-111, a high-affinity N-type voltage-sensitive calcium channel antagonist, on morphine-induced respiratory depression in rats. Soc. Neurosci. Abstr. 21:1170.
6. Gohil, K., J. R. Bell, J. Ramachandran, and G. P. Miljanich. 1994. Neuroanatomical distribution of receptors for a novel voltage-sensitive calcium-channel antagonist, SNX-230 (omega-conopeptide MVIIC). Brain Res. 653:258-266.
7. Hanley, T. R., Jr., J. A. John-Greene, J. T. Young, L. L. Calhoun, and K. S. Rao. 1987. Evaluation of the effects of inhalation exposure to 1,3-dichloropropene on fetal development in rats and rabbits. Fundam. Appl. Toxicol. 8:562-570.
8. Hassenbusch, S. J., R. K. Portenoy, M. Cousins, E. Buchser, T. R. Deer, S. L. Du Pen, J. Eisenach, K. A. Follett, K. R. Hildebrand, E. S. Krames, R. M. Levy, P. P. Palmer, J. P. Rathmell, R. L. Rauck, P. S. Staats, L. Stearns, and K. D. Willis. 2004. Polyanalgesic Consensus Conference 2003: An update on the management of pain by intraspinal drug delivery - report of an expert panel. J. Pain Symptom Manage. 27:540-563.
9. Kirk, H. D., N. M. Berdasco, W. J. Breslin, and T. R. Hanley, Jr. 1995. Developmental toxicity of 1,2-dichloropropane (PDC) in rats and rabbits following oral gavage. Fundam. Appl. Toxicol. 28:18-26.
10. Miljanich, G. P. 1997. Venom peptides as human pharmaceuticals. Sci. Med. 4:6-15.
11. Miljanich, G. P. 2004. Ziconotide: Neuronal calcium channel blocker for treating severe chronic pain. Curr. Med. Chem. 11:3029-3040.
12. Miljanich, G. P., and J. Ramachandran. 1995. Antagonists of neuronal calcium channels: Structure, function, and therapeutic implications. Annu. Rev. Pharmacol. Toxicol. 35:707-734.
13. Newcomb, R., T. J. Abbruscato, T. Singh, L. Nadasdi, T. P. Davis, and G. Miljanich. 2000. Bioavailability of Ziconotide in brain: Influx from blood, stability, and diffusion. Peptides 21:491-501.
14. Newcomb, R., and G. Miljanich. 2002. Neurotoxins of cone snail venoms. In Handbook of neurotoxicology, ed. E. J. Massaro, 617-651, Totowa, NJ: Humana Press.
15. Olivera, B. M., L. J. Cruz, V. de Santos, G. W. LeCheminant, D. Griffin, R. Zeikus, J. M. McIntosh, R. Galyean, J. Varga, W. R. Gray, and et al. 1987. Neuronal calcium channel antagonists. Discrimination between calcium channel subtypes using omega-conotoxin from Conus magus venom. Biochemistry 26:2086-2090.
16. PRIALT [package insert]. 2005. San Diego, CA: Elan Pharmaceuticals, Inc.
17. PRIALT [summary of product characteristics]. 2005. Shannon, County Clare, Ireland: Elan Pharma International Ltd.
18. Rauck, R. L., M. S. Wallace, M. S. Leong, M. MineHart, L. R. Webster, S. G. Charapata, J. E. Abraham, D. E. Buffington, D. Ellis, and R. Kartzinel. 2006. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J. Pain Symptom Manage. 31:393-406.
19. Rodwell, D. E., R. D. Wilson, M. D. Nemec, and M. D. Mercieca. 1989. Teratogenic assessment of 2,4-dichlorophenol in Fischer 344 rats. Fundam. Appl. Toxicol. 13:635-640.
20. Shopp, G. M., M. J. Skov, and T. L. Yaksh. 2004. Subchronic toxicity of ziconotide administered by continuous intrathecal infusion in rat and dog. The Toxicologist (suppl. to Toxicol. Sci.). 78 (S-1). Abstract 2097.
21. Skov, M. J., G. M. Shopp, L. Pouliot, K. J. Robinson, and J. C. Beck. 2004. A teratology study of ziconotide utilizing double-staining and postnatal examinations to elucidate delayed ossification. The Toxicologist CD - An Official Journal of the Society of Toxicology 78:Abstract: 2097.
22. Staats, P. S., T. Yearwood, S. G. Charapata, R. W. Presley, M. S. Wallace, M. Byas-Smith, R. Fisher, D. A. Bryce, E. A. Mangieri, R. R. Luther, M. Mayo, D. McGuire, and D. Ellis. 2004. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA 291:63-70.
23. Terlau, H., and B. M. Olivera. 2004. Conus venoms: A rich source of novel ion channel-targeted peptides. Physiol. Rev. 84:41-68.
24. U.S. Department of Agriculture. 1989. Animal Welfare; Final Rules; 9 CFR Parts 1 and 2. Federal Register 54:36112-36163.
25. Wallace, M. S., S. G. Charapata, R. Fisher, M. Byas-Smith, P. S. Staats, M. Mayo, D. McGuire, and D. Ellis. 2006. Intrathecal ziconotide in the treatment of chronic nonmalignant pain: A randomized, double-blind, placebo-controlled clinical trial. Neuromodulation 9:75-86.
26. Wang, Y. X., S. Bezprozvannaya, S. S. Bowersox, L. Nadasdi, G. Miljanich, G. Mezo, D. Silva, K. Tarczy-Hornoch, and R. R. Luther. 1998. Peripheral versus central potencies of N-type voltage-sensitive calcium channel blockers. Naunyn Schmiedeberg's Arch. Pharmacol. 357:159-168.
27. Yaksh, T. L., K. A. Horais, N. A. Tozier, J. W. Allen, M. Rathbun, S. S. Rossi, C. Sommer, C. Meschter, P. J. Richter, and K. R. Hildebrand. 2003. Chronically infused intrathecal morphine in dogs. Anesthesiology 99:174-187.
28. Yaksh, T. L., J. Provencher, A. W. de Kater, R. R. Dean, and S. Bowersox. 1999. Kinetics of ziconotide given intrathecally in dog. The Toxicologist (suppl. to Toxicol. Sci.). 48 (S-1). Abstract 1001.